← Back to Clinical Trials
Recruiting NCT05342441

NCT05342441 Optimizing Graft Selection for ACL Reconstruction

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05342441
Status Recruiting
Phase
Sponsor Hvidovre University Hospital
Condition ACL - Anterior Cruciate Ligament Rupture
Study Type INTERVENTIONAL
Enrollment 150 participants
Start Date 2022-05-09
Primary Completion 2026-05

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 40 Years
Study Type INTERVENTIONAL
Interventions
QT graftST/Gr graftBPTB graft

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 150 participants in total. It began in 2022-05-09 with a primary completion date of 2026-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Purpose: To investigate the differences between the three most common methods for reconstruction of the anterior cruciate ligament (ACL), to support the development of the best method for the individual patient. Main research area: ¨ Sports Orthopedic Surgical research. State of the art: Every year in Denmark 2500 patients receive surgical reconstruction surgery to replace a ruptured ACL. Many patients experience a decline in knee function and 4-12% suffer a new ACL rupture within 5 years. According to data from the Danish ACL register, three methods of reconstruction are most prevalent, but with large variation between hospitals. This indicates lack of consensus on optimal surgical procedure. Design: Assessor-blinded randomized controlled study. 150 patients aged 18-40 with ruptured ACL are allocated to reconstruction with tendon(s) harvested from either the semitendinosus and gracilis, or the patella tendon, or the quadriceps tendon. Patient follow-up will be conducted preoperatively and 1, 6, 12, 24 months postoperatively. Primary technologies and outcomes: * Patient-reported knee-joint function, quality of life and donor-site morbidity is obtained with standardized questionnaires. Primary outcome is subjective knee function with the International Knee Documentation Committee evaluation form (IKDC) * Instrumented analysis of knee-joint coordination and neuromuscular control including 3-D motion capture and electromyography (EMG) during single leg jumps, landings and change-of-direction. Measurement of maximal explosive muscle power in knee extension and flexion. Primary outcome is relative difference between injured and healthy leg in rate of force development (RFD-LSI). * Standard clinical knee examination of range of motion and instrumented examination of knee-joint stability. * Magnetic Resonance Imaging (MRI) of the thigh muscles for examination of muscle morphology. The trial is designed for publication in three primary publications 1. \- Patient reported effect of graft choice in ACL reconstruction 2. \- Biomechanical effect of graft choice in ACL reconstruction 3. \- Clinical effect of graft choice in ACL reconstruction Additional secondary publications are in the pipeline. Reference to primary protocol and results will always be emphasized in secondary publication to ensure methodological transparency.

Eligibility Criteria

List of Inclusion criteria * clinically confirmed first-time ACL rupture * Current injury sustai´ned within 2 years * high activity level prior to ACL rupture (Tegner score ≥ 3) and personal goal of returning to physical activity. List of preoperative exclusion criteria * Inadequate Danish language skills to answer questionnaires. * Prior ligament surgery in the injured knee * Prior ligament surgery in the non-injured knee * Instability of the non-injured knee * Known osteoarthritis (Kelgren Lawrence score ≥ 2) * Prior open surgery to either knee * Prior severe fracture involving knee joint surfaces * Prior severe injury to thigh muscles in either leg (e.g. tear or compartment) * Prior severe injury to the patella tendon of either knee (e.g. subluxation) * Medical condition preventing full participation (e.g. active cancer, - rheumatoid arthritis) * Psychiatric condition preventing full participation * Pregnancy * Obesity (BMI \> 30) List of Perioperative exclusion criteria (Arthroscopy) * Medial meniscus lesion \> 50% * Lateral meniscus lesion \> 50% * Treated Meniscal root lesion or radial meniscal tear that require restrictive regimen * Cartilage lesion \>2cm2, Articular cartilage injury classification (ICRS) grade 3 * Concurrent ligament injury (except medial collateral ligament (MCL) lesion grade 1-2)

Contact & Investigator

Central Contact

Merete B Speedtsberg, MSc

✉ MSPE0006@regionh.dk

📞 +45 38622381

Principal Investigator

Per Hölmich, D.M.Sc/D.Sc

STUDY DIRECTOR

Hvidovre UH

Frequently Asked Questions

Who can join the NCT05342441 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 40 Years, studying ACL - Anterior Cruciate Ligament Rupture. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05342441 currently recruiting?

Yes, NCT05342441 is actively recruiting participants. Contact the research team at MSPE0006@regionh.dk for enrollment information.

Where is the NCT05342441 trial being conducted?

This trial is being conducted at Hvidovre, Denmark.

Who is sponsoring the NCT05342441 clinical trial?

NCT05342441 is sponsored by Hvidovre University Hospital. The principal investigator is Per Hölmich, D.M.Sc/D.Sc at Hvidovre UH. The trial plans to enroll 150 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology